Highlights

  • Radiopharm Theranostics (ASX:RAD) raised approximately $16 million following back-to-back positive clinical-trial readouts announced on 22 July 2026.
  • RAD101, a Fluorine-18 brain-metastases PET imaging agent, met its Phase 2b primary endpoint with 93% concordance to MRI and 86% sensitivity in evaluable patients; a US Phase 3 pivotal trial is planned for Q4 2026.
  • RAD204, a PD-L1-targeting lutetium-177 single-domain antibody therapy, produced a RECIST-confirmed durable partial response, with one patient progression-free beyond seven months and no dose-limiting toxicities.
  • Radiopharm carries a diversified oncology pipeline including RAD202 (HER2), RAD402 (prostate/KLK3) and RV01 (B7H3), and is dual-listed on the ASX and Nasdaq (RADX).
  • Investors should watch the RAD101 Phase 3 start, RAD204 dose selection, cash runway and specificity data due in Q4 2026.

Radiopharm Theranostics (ASX:RAD) has capped a landmark day for its clinical pipeline by moving to strengthen its balance sheet, raising about $16 million on the back of positive results from not one but two separate cancer trials. The clinical-stage radiopharmaceutical developer, dual-listed on the ASX and Nasdaq (RADX), reported the twin readouts on 22 July 2026 — a diagnostic imaging win and a therapeutic win landing on the same day — in what the market quickly framed as a clinical-trial double delight.

For a developmental biotech that lives and dies on trial data, two supportive results arriving together is precisely the kind of catalyst that can re-rate a story and open a funding window. Radiopharm appears to have taken that window, tapping investors to push its lead assets toward larger, registration-focused studies.

What Has Happened

Radiopharm released results from two distinct programs. The first was the Phase 2b trial of RAD101, a novel PET imaging agent designed to detect brain metastases. The study met its primary efficacy endpoint, reporting 93% concordance between RAD101 PET imaging and MRI across evaluable lesions. In the subset of 14 patients with six-month follow-up or biopsy confirmation, RAD101 showed 86% sensitivity (12 of 14). The trial evaluated 30 patients in total, and specificity data is expected in the fourth quarter of 2026.

The second readout came from RAD204, a therapeutic candidate in a Phase 1 dose-escalation study. Here the company reported its first RECIST-confirmed durable partial response in a patient with advanced solid tumours who had progressed following immunotherapy. That patient recorded a 43% reduction in target lesions after the second dose, a response that was confirmed and broadly maintained across subsequent cycles, and remained progression-free for more than seven months. A second patient showed early tumour shrinkage and was continuing on treatment. Importantly, management reported no dose-limiting toxicities across the cohorts dosed to date, with the highest tested level at 90 millicuries (mCi).

Alongside the data, Radiopharm moved to reinforce its funding, with the company reported to have raised in the order of $16 million to support ongoing patient dosing, Phase 3 preparation and broader pipeline advancement. The company has previously established mechanisms for accessing capital in both Australia and the United States, and this raise adds to a balance sheet that has been topped up several times over the past year as the pipeline has matured.

Why It Matters

Two supportive trials in a single announcement is unusual for a company of Radiopharm's size, and the combination speaks to the breadth of its platform. RAD101 addresses a genuine clinical gap: there is currently no FDA-approved PET imaging product specifically for brain metastases, and distinguishing recurrent tumour from treatment-related change after radiotherapy is a persistent challenge for oncologists. Management has pointed to an addressable market it estimates at more than US$600 million, and RAD101 already holds FDA Fast Track designation for this indication.

RAD204, meanwhile, matters because it targets one of oncology's most important pathways — PD-L1 — but as a radiotherapy rather than a conventional checkpoint antibody. Demonstrating a confirmed, durable response in patients who have already failed immunotherapy is an early but meaningful signal that the approach can produce tumour shrinkage where other options have run out. Together, the readouts support the company's core thesis that its protein-engineered platform can generate both diagnostics and therapeutics.

The associated capital raise is equally significant in a practical sense. Early-stage radiopharmaceutical development is capital-intensive, and having fresh funds in hand immediately after positive data reduces the risk that promising programs stall for want of cash.

Inside the Radiopharm Pipeline

Radiopharm describes itself as a developer of a diversified portfolio of radioactive drug products for both diagnostic and therapeutic uses, built on protein-engineered molecules, antibodies, nanobodies, peptides and small molecules. The two trials in the headline are the most advanced expressions of that platform, but they sit within a wider stable.

RAD101 — brain-metastases imaging

RAD101 is a small-molecule PET imaging agent radiolabelled with Fluorine-18 that targets fatty acid synthase (FASN), an enzyme overexpressed in many cerebral metastases. The Phase 2b result positions it to advance into an intended US registrational Phase 3 program, which the company has flagged for initiation in the fourth quarter of 2026. Radiopharm has also referenced a manufacturing arrangement with Siemens Healthineers to support supply — an important consideration for any imaging agent that must be produced and distributed reliably at scale.

RAD204 — PD-L1 radiotherapy

RAD204 is a single-domain antibody (also described as a nanobody) that targets PD-L1 and delivers the therapeutic isotope lutetium-177 directly to tumour cells. The Phase 1 data is intended to inform the recommended dose for a planned Phase 2 study in PD-L1-associated malignancies, including non-small cell lung cancer. Encouragingly, the company reported limited kidney uptake in the lead responder, a relevant safety marker for this class of therapy.

The broader stable

Beyond the two headline assets, Radiopharm is progressing RAD202, a HER2-targeted radiotherapy in Phase 1 that has cleared early dose cohorts without dose-limiting toxicities; RAD402, a prostate-cancer therapy targeting KLK3 (PSA) that entered Phase 1 earlier in 2026 as a differentiated alternative to PSMA-based approaches; and RV01, a B7H3-targeted candidate in a Phase 1 basket trial across multiple tumour types. This spread gives the company several independent shots on goal.

Key Financial and Operational Details

Radiopharm is a pre-revenue, clinical-stage business, so its value rests on pipeline progress and its ability to fund that progress. The roughly $16 million raise follows a series of capital-markets actions over the prior year, including a larger institutional placement and share purchase plan in late 2025 and the establishment of a US at-the-market facility to broaden access to American investors. The company has also benefited from an Australian R&D tax incentive receipt of approximately A$5.89 million in July 2026, which helps offset clinical spend.

Strategic validation has come from Lantheus, a US radiopharmaceutical specialist that took a shareholding in Radiopharm, underscoring institutional interest in the platform. Leadership sits with CEO and Managing Director Riccardo Canevari and Chairman Paul Hopper. Management has framed the RAD101 endpoint as strong validation of its approach and a springboard into a registrational program — a characterisation investors should weigh as guidance rather than a guarantee.

Potential Catalysts

Several near-term events could move the story. The most consequential is the planned initiation of the RAD101 Phase 3 pivotal trial in the fourth quarter of 2026, alongside the RAD101 specificity dataset due in the same period. On the therapeutic side, completion of RAD204 dose escalation and confirmation of a recommended Phase 2 dose would be a clear step forward, as would additional responses in the ongoing cohorts.

Progress across RAD202, RAD402 and RV01 provides further optionality, and any new partnering, licensing or strategic-investment activity — building on the Lantheus relationship — could act as external validation. Continued clarity on cash runway following the latest raise would also reassure the market.

Material Risks and Uncertainties

The risks are substantial and typical of the sector. Early-stage clinical data, however encouraging, does not guarantee success in larger trials; RAD204's results rest on a small number of patients, and single responses can look very different in a broader population. RAD101 still needs to deliver specificity data and then clear a full Phase 3 program before any regulatory approval is possible.

As a pre-revenue developer, Radiopharm remains dependent on capital markets, and repeated raises — including this one — can dilute existing shareholders. Radiopharmaceutical manufacturing, supply logistics and regulatory pathways are complex, and competition in both PD-L1 and prostate targeting is intense. The share price of a stock like this can be volatile in both directions, and investors should treat management's forward timelines as targets that may shift.

What Investors Should Watch Next

For Radiopharm Theranostics (ASX:RAD), the signposts are clear. First, watch for confirmation and timing of the RAD101 Phase 3 pivotal trial and the Q4 2026 specificity data. Second, monitor RAD204's continued dose escalation and any move to a Phase 2 study. Third, keep an eye on the balance sheet — how far the roughly $16 million raise, combined with existing facilities and the R&D rebate, extends the cash runway. Finally, track newsflow across the earlier-stage assets and any further strategic or partnering developments that would validate the platform beyond its lead programs.

Conclusion

The simultaneous readouts from RAD101 and RAD204 mark one of the more significant days in Radiopharm Theranostics' (ASX:RAD) history, giving the company supportive data across both the diagnostic and therapeutic sides of its platform and prompting a roughly $16 million capital top-up to fund the next phase of work. The RAD101 primary-endpoint result and the confirmed durable response in RAD204 genuinely strengthen the investment case.

Equally, this remains an early-stage, pre-revenue business whose lead programs must still navigate larger trials, regulatory scrutiny and ongoing funding needs. The double trial win buys Radiopharm momentum and cash; converting that into approved products is the harder task that lies ahead.

Disclaimer: Radiopharm Theranostics Ltd (ASX:RAD) is a client of Kalkine Media Pty Ltd (Kalkine Media), an affiliate of Kalkine. However, under no circumstances have Kalkine or its related entities been, directly or indirectly influenced in making any recommendation concerning Company as contained in this article, and no form of compensation is or will be received by Kalkine, Kalkine Media or Kalkine’s other related entities for the publication of this article.